Hapvida says review of 947,000 health plan contracts is routine, not undisclosed market-moving event
Reuters2026/08/14 22:55- Hapvida clarified that media reports on “high double-digit” price hikes stem from its 2Q26 results materials filed on Aug. 12.
- About 947,000 beneficiaries, or 11% of its health-plan base, face commercial review due to weak profitability or delinquency.
- Contracts will be repriced case by case over the next 12 months at renewal dates, or discontinued if economics cannot be restored.
- “High double-digit” was described as a qualitative range, with intended average increases above broader portfolio levels, subject to negotiation.
- Hapvida said it has not quantified EBITDA impact, viewing any improvement as qualitative, with limited revenue exposure given lower ticket size.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ivy League’s space gamble: Harvard reveals $2.2 billions SpaceX position, its largest single stock holding
Harvard University Investment Management Company disclosed that it holds $2.2 billion worth of SpaceX shares, making it the largest single stock position in its $4.3 billion US equity portfolio. This holding originated from Harvard’s early investment in SpaceX through venture capital funds, and the position has significantly appreciated after SpaceX’s public listing in June this year. The University of California also disclosed a roughly $1 billion position in SpaceX during the same period. Over the past decade, endowment funds from several universities have made substantial bets on private tech assets.
Circle obtains Major Payment Institution license in Singapore
Crypto prices
More
